|October 24, 2011|
More Relevant Cancer Models Available
October is Breast Cancer Awareness Month. More than ever, new preclinical approaches are needed to support oncology research. Among the new tools are more relevant cancer models being developed by the Primary Human Tumors Consortium (PHTC) formed by The Jackson Laboratory (JAX), the University of California, Davis, and other cancer research institutions. The PHTC is a publicly available library of primary human tumors for cancer research and drug development and is housed in Sacramento at our in vivo pharmacology services facility.
|The NSG mouse is one of the most immunodeficient mouse models available. It has no mature T, B, or NK cells, is long-lived, is ideally suited to propagate human tissue, and has outstanding utility in cutting-edge cancer research.|
To date, the PHTC has engrafted more than 225 patient-derived tumors into NSG mice and established more than 50 PDX models. Among the new models available are two mammary carcinoma models, including one triple negative model. Learn more about these two models and their availability.
In the coming weeks, researchers will have two great opportunities to learn more about the PHTC and PDX cancer models:
|Dr. Neal Goodwin is Program Director of The Jackson Laboratory's Cancer Services.|
On November 8, at the Phacilitate Oncology Leaders' Forum, held in Boston from November 7-9, at focus session 2 ("Advanced translational models in oncology: Under-estimated, under-valued tools?"), JAX scientist Dr. Neal Goodwin, who spearheaded the PHTC's formation, will speak about the PHTC and PDX models from 2:20-40 PM (ET in US). His talk is titled "The JAX Cancer Consortium: Changing the course of clinical advancement."
For more information on the PHTC and PDX tumor models, please contact email@example.com.